TY - JOUR
T1 - Adjuvant treatment in resected non-small cell lung cancer
T2 - Current and future issues
AU - Remon, Jordi
AU - Lianes, Pilar
AU - Martínez, Susana
AU - Velasco, Montserrat
AU - Querol, Rosa
AU - Zanui, Montserrat
PY - 2013/11/1
Y1 - 2013/11/1
N2 - The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has been surgical resection. In the last five years two phase III trials have provided evidence of adjuvant platinum-based chemotherapy for completely resected stage II-IIIA patients. We review the evidence supporting adjuvant therapy in early-stage NSCLC; we discuss new issues surrounding adjuvant therapy such as treatment in the elderly-unfit population, treatment toxicity and its influence on outcomes, the importance of histology and gender in adjuvant treatment; and we discuss the future landscape of early-stage NSCLC research, namely, therapeutic strategies exploiting pharmacogenomic and gene-expression profiling, in an attempt to customize the treatment.
AB - The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has been surgical resection. In the last five years two phase III trials have provided evidence of adjuvant platinum-based chemotherapy for completely resected stage II-IIIA patients. We review the evidence supporting adjuvant therapy in early-stage NSCLC; we discuss new issues surrounding adjuvant therapy such as treatment in the elderly-unfit population, treatment toxicity and its influence on outcomes, the importance of histology and gender in adjuvant treatment; and we discuss the future landscape of early-stage NSCLC research, namely, therapeutic strategies exploiting pharmacogenomic and gene-expression profiling, in an attempt to customize the treatment.
KW - Adjuvant chemotherapy
KW - Lung cancer
KW - Stage IB-IIIA
UR - http://www.scopus.com/inward/record.url?scp=84885841274&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2013.05.017
DO - 10.1016/j.critrevonc.2013.05.017
M3 - Review article
C2 - 23809199
AN - SCOPUS:84885841274
SN - 1040-8428
VL - 88
SP - 375
EP - 386
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 2
ER -